David Hoang
Stock Analyst at Deutsche Bank
(0.86)
# 3,582
Out of 4,818 analysts
38
Total ratings
24.14%
Success rate
-14.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $27.16 | +91.49% | 2 | Mar 27, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Hold | $124 → $99 | $59.44 | +66.55% | 6 | Mar 19, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $37.65 | +77.95% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $36.71 | +202.41% | 1 | Feb 11, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $55 | $28.98 | +89.79% | 2 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $14.88 | +108.33% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $21.48 | +202.61% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $104.33 | +68.70% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $8.33 | +44.06% | 1 | Feb 11, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $23 | $14.66 | +56.89% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $103.25 | +53.03% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.02 | +586.27% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $8 | $7.64 | +4.78% | 1 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.56 | +349.44% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.51 | +355.84% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $242.16 | -9.15% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $13.05 | +513.03% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.89 | +235.27% | 1 | Dec 7, 2022 |
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $27.16
Upside: +91.49%
Sarepta Therapeutics
Mar 19, 2025
Maintains: Hold
Price Target: $124 → $99
Current: $59.44
Upside: +66.55%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $37.65
Upside: +77.95%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $36.71
Upside: +202.41%
Harmony Biosciences Holdings
Feb 11, 2025
Initiates: Buy
Price Target: $55
Current: $28.98
Upside: +89.79%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $14.88
Upside: +108.33%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $21.48
Upside: +202.61%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $104.33
Upside: +68.70%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $8.33
Upside: +44.06%
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $30 → $23
Current: $14.66
Upside: +56.89%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $103.25
Upside: +53.03%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.02
Upside: +586.27%
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $7.64
Upside: +4.78%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $3.56
Upside: +349.44%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.51
Upside: +355.84%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $242.16
Upside: -9.15%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $13.05
Upside: +513.03%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.89
Upside: +235.27%